-
公开(公告)号：US20230312511A1
公开(公告)日：2023-10-05
申请号：US18111241
申请日：2023-02-17
申请人： The United States of America, as represented by the Secretary, Department of Health and Human , The University of Kansas , The University of North Carolina at Chapel Hill
发明人： David R. Sibley , Amy Elizabeth Moritz , R. Benjamin Free , Joseph P. Steiner , Noel Terrence Southall , Marc Ferrer , Xin Hu , Warren S. Weiner , Jeffrey Aubé , Kevin Frankowski
IPC分类号： C07D401/12 , A61P25/28 , C07D209/42 , C07D213/65 , C07D213/81 , C07D235/24 , C07D295/185 , C07D307/85 , C07D317/64 , C07D333/70 , C07D405/12 , C07D409/12 , C07D471/04
CPC分类号： C07D401/12 , A61P25/28 , C07D209/42 , C07D213/65 , C07D213/81 , C07D235/24 , C07D295/185 , C07D307/85 , C07D317/64 , C07D333/70 , C07D405/12 , C07D409/12 , C07D471/04
摘要： The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof
The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.-
公开(公告)号：US20230272120A1
公开(公告)日：2023-08-31
申请号：US17998177
申请日：2021-05-10
发明人： Mei He
摘要： The present disclosure provides immunomagnetic compositions and their methods of use, in particular magnetic particles conjugated to peptides that bind and capture extracellular vesicles.
-
公开(公告)号：US20230258640A1
公开(公告)日：2023-08-17
申请号：US18051422
申请日：2022-10-31
发明人： Paul W. DEMPSEY , Spencer HANTULA , Cristina-Mihaela Sandu APARICIO , Stefan H. BOSSMANN , Christopher M. SORENSEN , Obdulia COVARRUBIAS-ZAMBRANO , Jose COVARRUBIAS
IPC分类号： G01N33/573 , G01N33/543 , G01N33/542 , G01N33/533 , G01N33/551
CPC分类号： G01N33/573 , G01N33/54346 , G01N33/542 , G01N33/533 , G01N33/551
摘要： Provided herein are graphene biosensors and related core particles, compositions methods and systems in which more than one pristine graphene sheet is coated with a coating layer of an organic or inorganic material to provide a core graphene particle, to which detectable components comprising a detectable moiety and a peptide linkage are attached through binding of the peptide linkage.
-
公开(公告)号：US20220105151A1
公开(公告)日：2022-04-07
申请号：US17495556
申请日：2021-10-06
发明人： Peter S. N. Rowe
摘要： A method of treating or inhibiting a kidney disorder can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for the kidney disorder (treat disease) and/or inhibit development of the kidney disorder (prophylactic). The kidney disorder can be selected from the group consisting of chronic kidney disease mineral bone disorder (CKD-MBD), calciphylaxis, nephrogenic systemic fibrosis (NSF), end stage renal disease, and combinations thereof. The therapy can include inhibiting vascular calcification (VC), hard tissue calcification, soft tissue calcification, mineralization, or combinations thereof in the subject with the ASARM peptide. A method of inhibiting mineralization can include administering a therapeutically effective amount of the ASARM peptide to provide a treatment for inhibit mineralization in the subject. A method of treating hyperphosphatemia can include administering a therapeutically effective amount of the ASARM peptide to a subject to provide a treatment for hyperphosphatemia.
-
公开(公告)号：US20220073999A1
公开(公告)日：2022-03-10
申请号：US17514724
申请日：2021-10-29
发明人： Mei He
IPC分类号： C12Q1/6886 , A61K47/69 , G01N33/574 , G01N33/543 , B03C1/015 , B03C1/30 , B01L3/00 , A61K49/00
摘要： Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.
-
公开(公告)号：US20220056002A1
公开(公告)日：2022-02-24
申请号：US17416172
申请日：2019-12-20
IPC分类号： C07D311/16 , G01N33/547
摘要： A photocleavable heterobifunctional linker can include a structure of Formula (A) wherein coumarin is any coumarin or coumarin derivative; R, R9, and R10 are each independently a chemical moiety; R1 is a hydrogen, protecting group, leaving group, substrate, or capture entity; R2 is a hydrogen, hydroxyl, halide, alkoxy, anhydride, amino, protecting group, leaving group, substrate, or capture entity; L1 is a sub-linker; and L2 is a sub-linker. A capture device can include the photocleavable bifunctional linker having a structure of Formula (A) as provide herein, wherein R1 is a substrate. A method of capturing a target substance can include: providing the capture device having the photocleavable bifunctional linker with the structure of Formula (A) and contacting a target substance to the capture moiety such that the target substance is captured. Irradiating the linker with light can cleave the linker, thereby releasing the target substance from the substrate.
-
公开(公告)号：US20220054255A1
公开(公告)日：2022-02-24
申请号：US17517027
申请日：2021-11-02
发明人： Michael Detamore , Lindsey Ott , Robert Weatherly
摘要： An implant can include a plurality of polymeric fibers associated together into a fibrous body. The fibrous body is capable of being shaped to fit a tracheal defect and capable of being secured in place by suture or by bioadhesive. The fibrous body can have aligned fibers (e.g., circumferentially aligned) or unaligned fibers. The fibrous body can be electrospun. The fibrous body can have a first characteristic in a first gradient distribution across at least a portion of the fibrous body. The fibrous body can include one or more structural reinforcing members, such as ribbon structural reinforcing members, which can be embedded in the plurality of fibers. The fibrous body can include one or more structural reinforcing members bonded to the fibers with liquid polymer as an adhesive, the liquid polymer having a substantially similar composition of the fibers.
-
公开(公告)号：US20220008474A1
公开(公告)日：2022-01-13
申请号：US17488702
申请日：2021-09-29
发明人： Amara Seng , Ryan Fischer , Thomas Yankee , Mary Markiewicz , John Szarejko
IPC分类号： A61K35/17 , C12N15/86 , C12N5/0783
摘要： Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+ Helios+ eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
-
公开(公告)号：US11162143B2
公开(公告)日：2021-11-02
申请号：US17236561
申请日：2021-04-21
发明人： Mei He
IPC分类号： G01N27/00 , B03C5/00 , G01N27/12 , C12Q1/6886 , A61K47/69 , G01N33/574 , G01N33/543 , B03C1/015 , B03C1/30 , B01L3/00 , A61K49/00
摘要： Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.
-
公开(公告)号：US11160832B2
公开(公告)日：2021-11-02
申请号：US16924950
申请日：2020-07-09
发明人： Amara Seng , Ryan Fischer , Thomas Yankee , Mary Markiewicz , John Szarejko
IPC分类号： C12N5/00 , A61K35/17 , C12N15/86 , C12N5/0783
摘要： Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
-
-
-
-
-
-
-
-
-
搜索结果
134 条记录 (耗时 0.038 秒)
